Kexing Biopharm's Overseas Product Paclitaxel for Injection (Albumin-Bound) Receives Marketing Approval in Switzerland

Article source：Aug 11,2026View： 429

Recently, Kexing Biopharm's overseas product, Paclitaxel for Injection (Albumin-Bound), received marketing authorization from the Swiss Agency for Therapeutic Products (Swissmedic).

Switzerland is one of the world's leading pharmaceutical hubs, recognized for its stringent regulatory standards and high market entry requirements. This approval marks another significant milestone for the product in the European pharmaceutical market.

Paclitaxel for Injection (Albumin-Bound) offers notable clinical advantages. Compared with conventional paclitaxel injection and paclitaxel liposome formulations, it demonstrates improved safety and enhanced patient compliance. The product has gained broad clinical recognition and holds indispensable therapeutic value in the treatment of various cancers.

Although Switzerland is a relatively small pharmaceutical market by volume, it is characterized by exceptionally high value. The country ranks among the world's highest in per-capita healthcare expenditure and maintains strong clinical demand for high-quality oncology therapies. The approval of albumin-bound paclitaxel will provide Swiss cancer patients with an additional treatment option.

Since receiving marketing authorization from the European Commission in 2024, the product has obtained marketing approvals in more than 40 countries and regions worldwide.

Looking ahead, leveraging its well-established overseas registration, market access, and commercialization capabilities, Kexing Biopharm will continue to accelerate the global commercialization of high-quality pharmaceutical products, providing patients worldwide with more accessible and affordable innovative treatment solutions.